Cancer Evolution during Immunotherapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 29100071.
- Also identified by DOI 10.1016/j.cell.2017.10.027 and PMC identifier 5755374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.
Medical subject headings
- Melanoma
- Nivolumab